09885 藥師幫
YSB
YSB
| Listing Date | 2023/06/28 |
| Listing Price | 20.000 |
Quote
Subscription Result
- Subscription Rate5.60x
- Guarantee One Lot Size6 lot
- One Lot Success Rate30.01%
|
|
|
|
|
|
|
|
|
|
IPO Detail
COMPANY PROFILE
YSB Inc. is a digital pharmaceutical platform serving businesses outside of hospitals in China. It recorded a GMV of RMB37.8 billion in 2022, representing a market share of 21% in China’s digital market of outside-of-hospital pharmaceutical circulation services.
--
The Group serves the largest digital pharmaceutical transaction and service network, including, among others, around 354,000 downstream pharmacies and around 173,000 primary healthcare institutions, as of 31 December 2022. Furthermore, it had 308,000 average number of monthly active buyers (“MAB”) in 2022, the highest among digital pharmaceutical platforms serving businesses outside of hospitals in China. The average number of monthly available stock keeping units (SKUs) transacted on its platform was around 3.3 million in 2022.
--
It strategically designed mapping strategy for its own warehousing networking and had built 20 smart warehouses in 19 cities as of 31 December 2022.
BASIC INFORMATION
| Market | Hong Kong (Main Board) |
| Business Nature | Health Care |
| Major Business Area | China |
| Board Lot | 200 |
GLOBAL OFFERING
| No. of Offer Shares | 15.81M shares |
| No. of International Offer Shares | 14.23M shares |
| No. of HK Offer Shares | 1.58M shares |
| Offer Price | $19.00 - $23.00 |
| Stock Code | 9885 |
| Sponsor(s) | China International Capital Corporation Hong Kong Securities Limited |
| Underwriter(s) | China International Capital Corporation Hong Kong Securities Limited, CMB International Capital Limited, ICBC International Securities Limited, ABCI Securities Company Limited, Fosun International Securities Limited, Futu Securities International (Hong Kong) Limited, Tiger Brokers (HK) Global Limited, Valuable Capital Limited, Patrons Securities Limited |
TIME TABLE
| Application Period | Jun 15 (Thu) - noon, Jun 20 (Tue) |
| Price Determination Date | Jun 20 (Tue) |
| Result Announcement Date | On or before Jun 27 (Tue) |
| Result Announcement Date | On or before Jun 27 (Tue) |
| Result Announcement Date | On or before Jun 27 (Tue) |
| Dealings in Shares commence on | Jun 28, 2023. (Wed) |
Reallocation of Shares Offered
| Times of HK Offer Shares Subscription | 15X - 50X | 50X - 100X | Over 100X |
| % of total shares reallocated to HK Offer | 30% | 40% | 50% |
Sales Statistics (HKD)
| Offer Price | $19.00 - $23.00 |
| Capitalization | 12.02B - 14.54B |
| NAV / share ($) | $-32.91 - $-32.48 (Unaudited pro forma adj NAV / share) |
Use Of Proceeds
| Assuming the offer price being at HKD 21.00, the net proceeds raised would be HKD 253.60M, of which |
| 45% : Further developing pharmaceutical circulation business |
| 25% : Further developing other businesses |
| 22% : Research and development |
| 8% : Working capital |
Related Document
| Prospectus |  Chinese Version | English Version |
| Remark： | The above information is referenced from the prospectus. |
| All data is calculated from the non- exercise rights(if applicable). |
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --Offer Price︰--
| Currency | : |
| Listing Price | : |
| Board Lot | : |
| Admission Fee* |
: |
| Subscribing Lot | : |
| Subscribing Fee | : |
| Subscribing Amount | : |
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).